Abstract
Importance Recent clinical trials of Aβ-targeting therapies in Alzheimer’s disease (AD) have demonstrated clinical benefit over 18-months, but their long-term impact on disease trajectory is not yet understood. We propose a framework for evaluating realistic long-term scenarios.
Objective To integrate data from recent phase 3 trials of the high-clearance Aβ-targeting antibodies with an estimate of the long-term patient-level natural history trajectory of the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score, to explore realistic long-term efficacy scenarios.
Data Sources Published results from recent phase 3 randomized clinical trials of high-clearance Aβ-targeting antibodies with completion between 2019 and 2023.
Study Selection All phase 3 studies of aducanumab, lecanemab, gantenerumab, and donanemab were included.
Main Outcomes and Measures Reported study results on CDR-SB estimated using categorical-time models.
Results Three distinct long-term efficacy scenarios were examined, ranging from conservative (enduring short-term delay), over intermediate (fading stage-dependent slowing), to optimistic (continued stage-independent slowing). In a hypothetical framework, we found that even modestly effective therapies with fading stage-dependent slowing could result in major delays of disease progression if initiated in the earliest stages of AD. In long-term scenarios for the treatment effects observed in recent positive phase 3 trials, we found that initiating the treatments in the early symptomatic stages, defined by the respective trial inclusion criteria, could delay the onset of severe dementia by 0.3-0.6 years (conservative), 1.1-1.9 years (intermediate), and 2.0-4.2 years (optimistic).
Conclusion and Relevance The findings provide insights into hypothetical long-term impact of Aβ-targeting treatments, highlighting the potential of maximizing clinical benefit with earlier intervention. This study underscores some of the complexities of evaluating and comparing Aβ-targeting therapies in the context of AD’s nonlinear disease trajectory and the need for considering both differences in trial populations and duration. Our work calls for studies with longer follow-up and results from early intervention trials to provide a comprehensive assessment of these therapies’ true long-term impact.
Competing Interest Statement
LLR is an employee and shareholder of Eli Lilly and Company. JC has provided consultation to Acadia, Actinogen, Acumen, AlphaCognition, Aprinoia, AriBio, Artery, Biogen, BioVie, Cassava, Cerecin, Diadem, EIP Pharma, Eisai, GemVax, Genentech, GAP Innovations, Janssen, Jocasta, Karuna, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, PRODEO, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, Suven, SynapseBio, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. AM reports no conflicts of interest. NV has received research support from Fondation Bettencourt-Schueller, Fondation Servier, Union Nationale pour les Intárêts de la Mádecine (UNIM), Fondation Claude Pompidou, Fondation Alzheimer and Fondation pour la Recherche sur l'Alzheimer; travel grant from the Movement Disorders Society, Merz-Pharma, UCB Pharma, and GE Healthcare SAS; is an unpaid local principal investigator or sub-investigator in NCT04241068 and NCT05310071 (aducanumab, Biogen), NCT05399888 (BIIB080, Biogen), NCT03352557 (gosuranemab, Biogen), NCT05463731 (remternetug, Eli-Lilly), NCT04592341 (gantenerumab, Roche), NCT03887455 (lecanemab, Eisai), NCT03828747 and NCT03289143 (semorinemab, Roche), NCT04619420 (JNJ-63733657, Janssen - Johnson & Johnson), NCT04374136 (AL001, Alector), NCT04592874 (AL002, Alector), NCT04867616 (bepranemab, UCB Pharma), NCT04777396 and NCT04777409 (semaglutide, Novo Nordisk), NCT05469360 (NIO752, Novartis), is an unpaid national coordinator for NCT05564169 (masitinib, ABScience), NCT (AD04, ADvantage Therapeutics GmbH); has given unpaid lectures in symposia organized by Eisai and the Servier Foundation; and has been an unpaid expert for Janssen and Johnson & Johnson, all outside of this work. MS has served on advisory boards for and received funding from Roche Diagnostics and Novo Nordisk (outside scope of submitted work)
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study included only published data from the following recent phase 3 trials of high-clearance Aβ-targeting antibodies: EMERGE and ENGAGE of aducanumab, CLARITY AD of lecanemab, GRADUATE I and II of gantenerumab, and TRAILBLAZER-ALZ 2 of donanemab.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
